Revvity (RVTY) Q2 2026 Earnings Beat: EPS Tops Estimates by 16%
As seen on the 24/7 Wall St. homepage on August 4, 2026.
Diagnostics carried the quarter with 11% pro forma organic growth and margin widening to 30.4% from 25.2%, enough to offset a 3% organic decline in Life Sciences. Management raised full-year pro forma guidance to $2.83B-$2.86B in revenue and $5.30-$5.40 adjusted EPS, and is plowing part of $16 million in tariff refunds back into growth investments.
Continue ReadingShow less
Revvity reported Q2 2026 adjusted EPS of $1.41, clearing the $1.217 consensus estimate by nearly 16% and continuing a streak of beats that stretches back to at least Q2 2024. Revenue came in at $729.7 million, about 3.8% above the $703.2 million Wall Street had expected. The quarter marks another instance where the company outpaced expectations on both the top and bottom lines.
The headline numbers were powered almost entirely by Diagnostics, where pro forma organic revenue grew 11% and segment margin expanded sharply to 30.4% from 25.2% a year earlier. Life Sciences moved in the opposite direction, posting a 3% organic decline, though the Diagnostics strength was more than enough to absorb that drag. Revvity also received $16 million in tariff refunds during the quarter and said it plans to channel a portion of that back into growth investments rather than simply returning it to the bottom line.
Sponsored
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Management's confidence showed up in updated full-year guidance: revenue is now expected to land between $2.83 billion and $2.86 billion on a pro forma basis, with adjusted EPS in the $5.30 to $5.40 range. Investors will want to watch whether the Life Sciences segment stabilizes in the back half of the year, and whether the tariff-funded investments begin to show up in forward results.
Mentioned: RVTY